Prior data collected between 2010 and 2018 showed that GLP-1RA had been prescribed for patients with progressively more advanced disease stage, frequent use of insulin and high prevalence of cardiovascular disease [10]. The gene discussed is INS; the disease is cardiovascular disorder.